PMID- 32782728
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1970-5565 (Print)
IS  - 1970-5557 (Electronic)
IS  - 1970-5557 (Linking)
VI  - 14
IP  - 2
DP  - 2020 Jul 6
TI  - Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm.
PG  - 490
LID - 10.4081/oncol.2020.490 [doi]
LID - 490
AB  - Anti-PD1 and anti-PD-L1 agents may have intrinsic and clinically relevant 
      differences in the treatment of non-small cell lung cancer (NSCLC) patients. By 
      reviewing currently available indirect evidence on these agents for NSCLC 
      treatment, highlighting possible inter- and intra-class dissimilarities, anti-PD1 
      agents showed a higher response rate and a better outcome when combined with 
      chemotherapy for the first-line treatment of patients with squamous and PD-L1 low 
      advanced NSCLC, as compared to anti-PD-L1 agents. Conversely, anti-PD-L1 agents 
      were responsible for less severe adverse events (AEs), particularly, 
      immunerelated AEs. These differences could be explained by their different 
      specific properties. Considering possible differences between anti-PD1 and 
      anti-PD-L1 agents could be clinically relevant for treatment tailoring and 
      inspiring new investigational approaches.
CI  - (c)Copyright: the Author(s).
FAU - Banna, Giuseppe Luigi
AU  - Banna GL
AD  - Deparment of Medical Oncology, Portsmouth Hospitals NHS Trust, United kingdom.
FAU - Cantale, Ornella
AU  - Cantale O
AD  - Deparment of Medical Oncology, Portsmouth Hospitals NHS Trust, United kingdom.
FAU - Bersanelli, Melissa
AU  - Bersanelli M
AD  - Medical Oncology Unit, Medicine and Surgery Department, University of Parma, 
      Parma, Italy.
FAU - Del Re, Marzia
AU  - Del Re M
AD  - Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and 
      Experimental Medicine, University of Pisa, Pisa, Italy.
FAU - Friedlaender, Alex
AU  - Friedlaender A
AD  - Oncology Department, Geneva University Hospital, Geneva, Switzerland.
FAU - Cortellini, Alessio
AU  - Cortellini A
AD  - Medical Oncology Unit, St. Salvatore Hospital, University of L'Aquila, Department 
      of Biotechnological and Applied Clinical Sciences, L'Aquila, Italy.
FAU - Addeo, Alfredo
AU  - Addeo A
AD  - Oncology Department, Geneva University Hospital, Geneva, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20200721
PL  - Switzerland
TA  - Oncol Rev
JT  - Oncology reviews
JID - 101519906
PMC - PMC7385529
OTO - NOTNLM
OT  - Immune-checkpoint inhibitor
OT  - PD-L1
OT  - PD1
OT  - immune-related adverse events
OT  - lung cancer
EDAT- 2020/08/13 06:00
MHDA- 2020/08/13 06:01
PMCR- 2020/07/21
CRDT- 2020/08/13 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/04/14 00:00 [accepted]
PHST- 2020/08/13 06:00 [entrez]
PHST- 2020/08/13 06:00 [pubmed]
PHST- 2020/08/13 06:01 [medline]
PHST- 2020/07/21 00:00 [pmc-release]
AID - 10.4081/oncol.2020.490 [doi]
PST - epublish
SO  - Oncol Rev. 2020 Jul 21;14(2):490. doi: 10.4081/oncol.2020.490. eCollection 2020 
      Jul 6.